- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00446316
Effect of Antacids on Gleevec® in Healthy Volunteers
June 21, 2016 updated by: Jan Beumer, University of Pittsburgh
Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)
This is a research study that will investigate the effects of antacids (often used to treat stomach upset) on Gleevec® (a drug that is FDA-approved to treat some types of cancer) in healthy volunteers.
Twelve healthy volunteers (six men and six women) will be recruited to complete the study.
This research study will compare Gleevec® in the body when taken with and without antacids.
Each volunteer will receive a 400 mg pill of Gleevec® on two occasions.
One one occasion they will take the dose of Gleevec® alone.
On another occasion, they will take the Gleevec® 15 minutes after taking a 20 mL dose of antacids.
Several blood samples will be drawn to measure the concentrations of Gleevec® and its breakdown products in the blood, with and without the influence of antacids.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, single-institution, randomized cross-over, fixed schedule study of the effects of Mg-Al-based antacids on Imatinib Mesylate (Gleevec®) pharmacokinetics.
Healthy volunteers will be recruited to participate in this study such that twelve subjects (6 men / 6 women) will complete the study.
Gleevec® pharmacokinetics will be assessed after oral administration of Gleevec® and after oral administration of Gleevec® with concomitant administration of magnesium-aluminum hydroxide-based antacid (Maalox).
Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15.
The antacids will be administered 15 minutes before the Gleevec® dose.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232 / 15213
- University of Pittsburgh Cancer Institute / Clinical and Translational Research Center (Hillman Cancer Center and Montefiore University Hospital locations)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy men or women 18 years of age or older. Healthy subjects are defined as individuals who are free from clinically significant illness or disease (such as coronary arterial disease, chronic heart failure, bleeding disorder, hypertension, chronic renal failure etc.) as determined by their medical history, physical examination, and laboratory studies.
- Body Mass Index (BMI) < 31 kg/m^2 (weight/height^2).
- Female subjects of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female subjects of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 7 days following discontinuation of study drug.
- Written, voluntary informed consent.
- Subjects participating in the protocol entitled "IRB: 0701014: Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257) (UPCI #06-088)" will be eligible for participation in this study provided they meet all other eligibility criteria for this study.
Exclusion Criteria:
- Abnormal marrow function as defined by leucocyte, neutrophil, or platelet counts outside of normal limits.
- Any evidence of renal dysfunction (proteinuria; serum creatinine > upper limit of normal; or if serum creatinine > upper limit of normal, a calculated creatinine clearance < 60 mL/min/1.73 m2).
- Impaired hepatic function (liver enzymes greater than the upper limit of normal or bilirubin outside the normal range).
- Taking any medications (including over the counter products), herbal products, mineral supplements or vitamins (other than a daily multivitamin preparation), other than contraceptives (for women), within 2 weeks of start of the study. All forms of contraceptive medication are permissible for this study and would not result in a female's exclusion from participation. Patients who take medications on a chronic basis, such as antihypertensive medications or thyroid replacement therapy, etc. are not eligible for the study.
- Subjects that have received any other investigational agents within 28 days of first day of study drug dosing.
- Female subjects who are pregnant or breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Gleevec plus antacids
Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
|
the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
Other Names:
Gleevec® will be administered at a dose of 400 mg.
Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15.
The antacids will be administered 15 minutes before the Gleevec® dose.
Other Names:
|
EXPERIMENTAL: Imatimib Mesylate (Gleevec®)
Gleevec® will be administered at a dose of 400 mg.
Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15.
The antacids will be administered 15 minutes before the Gleevec® dose.
|
Gleevec® will be administered at a dose of 400 mg.
Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15.
The antacids will be administered 15 minutes before the Gleevec® dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To define the effect of antacid administration on the pharmacokinetics (in particular the area under the Gleevec® plasma concentration versus time curve) of Gleevec® in healthy volunteers.
Time Frame: 15 days
|
15 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jan H. Beumer, PharmD., PhD, University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (ACTUAL)
October 1, 2008
Study Completion (ACTUAL)
October 1, 2008
Study Registration Dates
First Submitted
March 8, 2007
First Submitted That Met QC Criteria
March 9, 2007
First Posted (ESTIMATE)
March 12, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
June 22, 2016
Last Update Submitted That Met QC Criteria
June 21, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-088
- CSTI571BUS257 (OTHER: Sponsor Protocol Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Antacids (Mg-Al-based)
-
London School of Hygiene and Tropical MedicineUniversity Medical Center Nijmegen; Centre national de recherche et de formation...Completed
-
Medicines for Malaria VentureNucleus Network Ltd; Southern Star Research Pty Ltd.Completed
-
Janssen Research & Development, LLCWithdrawn
-
Janssen Research & Development, LLCCompleted
-
University of LeipzigActive, not recruitingHeart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Preserved Ejection Fraction | Hypertrophy, Left Ventricular | Heart Failure NYHA Class IV | Cardiac Amyloidosis | Heart Failure With Mid Range Ejection FractionGermany
-
National Cancer Center, KoreaPusan National University Hospital; Chonnam National University Hospital; Kyungpook... and other collaboratorsActive, not recruitingGastric Cancer | Helicobacter Pylori InfectionKorea, Republic of
-
National Institute of Allergy and Infectious Diseases...CompletedAlphavirus Infections | Eastern Equine Encephalitis | Venezuelan Equine Encephalitis | Western Equine EncephalitisUnited States
-
Chulalongkorn UniversityCompletedHeartburn in PregnancyThailand
-
Janssen Research & Development, LLCTerminated
-
Sultan Qaboos UniversityKarolinska Institutet; Nova BiomedicalRecruitingType 2 Diabetes | Magnesium DisorderOman